M
Metsera
Metsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases
About Metsera
Metsera is a clinical stage biopharmaceutical company focused on developing innovative medicines and solutions for obesity and metabolic diseases. Founded by Population Health Partners and ARCH Venture Partners, Metsera leverages a proprietary library of over 20,000 incretin and non-incretin peptides and monoclonal antibodies to create potential best-in-class treatments. The company aims to reduce the physical, emotional, and economic burdens of obesity, a significant health and social challenge. Metsera's business model involves accelerating the development of new medicines through extensive R&D and large-scale business processes, targeting both consumers and investors. The company generates revenue by advancing its proprietary medicines through clinical trials and eventually bringing them to market. Metsera serves a diverse client base, including patients suffering from obesity and metabolic diseases, healthcare providers, and investors looking for innovative healthcare solutions. Operating in the biopharmaceutical market, Metsera is committed to making life healthier, happier, and longer through its next-generation medicines, technologies, and support systems.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2025
Open roles
Metsera in the New York City ecosystem
The Metsera office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A18 investors entered at this stage
ARCH Venture Partners
Population Health Partners
SoftBank
Newpath Partners
GV
F-Prime
Mubadala Capital
Venrock
Wellington Management
Fidelity Investments
RA Capital Management
Deep Track Capital
SymBiosis
Viking Global InvestorsJanus Henderson Investors
Alpha Wave Global
T. Rowe Price
SoftBank Vision Fund
Series B and later11 investors entered at this stage
- DCDeep Track Capital
Fidelity Investments
RA Capital Management
Venrock
T. Rowe Price
SoftBank Vision Fund
Alpha Wave GlobalJanus Henderson Investors
- VIViking Global Investors
Wellington Management- SYSymBiosis
Source: Dealroom Talent Intelligence.
See Metsera on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Pfizer lands up to $1.5B from Blackstone to fund obesity drug
Pfizer acquires Metsera (November 2025)